ERresQ

ERresQ is developing a first-in-class platform of small molecules that regulate ER stress by modulating all three branches of the Unfolded Protein Response (UPR), a mechanism inspired by endogenous neurotrophic factors MANF and CDNF. The pipeline includes both repurposed drugs and a new chemical entity, with initial applications in neurodegenerative diseases and diabetes. The company's strategy leverages the favorable pharmacokinetics of repurposed assets to potentially accelerate clinical development and market entry following proof-of-efficacy.

Platform for discovering small molecules that mimic neurotrophic factors MANF/CDNF to simultaneously modulate all three UPR sensors (IRE1α, PERK, ATF6), selectively targeting stressed cells to promote survival, reduce inflammation, and mitigate protein aggregation.

Competition includes companies developing single-pathway UPR inhibitors (e.g., IRE1α inhibitors) and other neuroprotective agents. ERresQ's differentiation lies in its holistic, multi-sensor modulation mimicking endogenous MANF/CDNF activity. Larger pharma companies with interests in neurodegeneration represent both potential competitors and future partners.